4.2 Review

Iron chelation therapy

期刊

EUROPEAN JOURNAL OF HAEMATOLOGY
卷 110, 期 5, 页码 490-497

出版社

WILEY
DOI: 10.1111/ejh.13935

关键词

chelation therapy; iron metabolism; iron overload

向作者/读者索取更多资源

Iron overload can be caused by a congenital impairment of iron regulation, increased intestinal iron absorption, or chronic transfusions. Diagnosing iron overload is challenging, with liver biopsy being the gold standard despite its invasiveness. Noninvasive techniques have allowed for better understanding of iron overload in different organs. Serum ferritin estimation is the most commonly used diagnostic tool, although it may not be specific. Hematological conditions such as myelodysplastic syndromes, sickle cell disease, and thalassemia can cause iron overload, which can be treated with chelators like deferiprone, deferoxamine, and deferasirox.
Iron overload is a pathological condition resulting from a congenital impairment of its regulation, increased intestinal iron absorption secondary to bone marrow erythroid hyperplasia, or a chronic transfusional regimen. In normal conditions, intracellular and systemic mechanisms contribute to maintaining iron balance. When this complex homeostatic mechanism fails, an iron overload could be present. Detecting an iron overload is not easy. The gold standard remains the liver biopsy, even if it is invasive and dangerous. Identifying iron using noninvasive techniques allowed a better understanding of the rate of iron overload in different organs, with a low risk for the patient. Estimating serum ferritin (mg/L) is the easiest and, consequently, the most employed diagnostic tool for assessing body iron stores, even if it could be a not specific method. The most common hematological causes of iron overload are myelodysplastic syndromes, sickle cell disease, and thalassemia. In all of these conditions, three drugs have been approved for the treatment of iron overload: deferiprone, deferoxamine, and deferasirox. These chelators have been demonstrated to help lower tissue iron levels and prevent iron overload complications, improving event-free survival (EFS). Nowadays, the decision to start chelation and which chelator to choose remains the joint decision of the clinician and patient.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据